Type II MAPs are found exclusively in nerve cells in mammals. These are the most well studied MAPs—MAP2 and tau (MAPT)—which participate in determining the structure of different parts of nerve cells, with MAP2 being found mostly in dendrites and tau in the axon. These proteins have a conserved C-terminal microtubule-binding domain and variable N-terminal domains projecting outwards, probably interacting with other proteins. MAP2 and tau stabilize microtubules, and thus shift the reaction kinetics in favor of addition of new subunits, accelerating microtubule growth. Both MAP2 and tau have been shown to stabilize microtubules by binding to the outer surface of the microtubule protofilaments. A single study has suggested that MAP2 and tau bind on the inner microtubule surface on the same site in tubulin monomers as the drug Taxol, which is used in treating cancer, but this study has not been confirmed. MAP2 binds in a cooperative manner, with many MAP2 proteins binding a single microtubule to promote stabilization. Tau has the additional function of facilitating bundling of microtubules within the nerve cell.
The function of tau has been linked to the neurological condition Alzheimers disease. In the nervous tissue of Alzheimers patients, tau forms abnormal aggregates. This aggregated tau is often severely modified, most commonly through hyperphosphorylation. As described above, phosphorylation of MAPs causes them to detach from microtubules. Thus, the hyperphosphorylation of tau leads to massive detachment, which in turn greatly reduces the stability of microtubules in nerve cells. This increase in microtubule instability may be one of the main causes of the symptoms of Alzheimer's disease.
In contrast to the MAPs described above, MAP4 (MAP4) is not confined to just nerve cells, but rather can be found in nearly all types of cells. Like MAP2 and tau, MAP4 is responsible for stabilization of microtubules. MAP4 has also been linked to the process of cell division.